OcuTerra Therapeutics
David S. Boyer, MD, is a world-renowned clinician, surgeon and educator. He is one of a select group of doctors at Cedars-Sinai Medical Center and at Good Samaritan Hospital who specialize in Ophthalmology. David is currently a leading investigator for various national clinical trials on retinal diseases and serving as an advisor for multiple research, educational and charitable institutions. David was also an investigator in the OTT166 Phase 1/Phase 2 clinical studies.
This person is not in the org chart
This person is not in any offices
OcuTerra Therapeutics
OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity